T-Neuro Pharma Welcomes Renowned Alzheimer’s Researcher Dr. Jeffrey Cummings as Chair of Scientific Advisory Board
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today the appointment of Dr. Jeffrey Cummings, MD, ScD as Chair of its Scientific Advisory Board (SAB). Dr. Cummings, a world-renowned expert in Alzheimer’s disease research and clinical trials, brings…
CHICAGO STAR: T-Neuro Pharma to Presents Expanded Alzheimer’s Disease Blood Biomarker Assay at Clinical Trials on Alzheimer’s Disease (CTAD) conference
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that it will present new research on its Diagnostic Biomarker assay for Alzheimer’s at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference. The poster presentation, scheduled for Oct….
BIOSPACE: T-Neuro Pharma’s Trailblazing Alzheimer’s Research Receives Acclaim in PNAS Commentary
T-Neuro Pharma, a leading biotechnology research company dedicated to developing innovative therapies for neurodegenerative diseases, announced that its groundbreaking research on Alzheimer’s disease has been highlighted in a commentary published in the Proceedings of the National Academy of Sciences USA (PNAS), a peer-reviewed journal of…
BIZJOURNAL: Albuquerque biopharma startup eyes investment after research paper publishes
An Albuquerque biopharmaceutical startup hopes publishing a “remarkable” study on its approach to detecting and diagnosing Alzheimer’s disease can help the company attract more investment and reach commercial success. Read the Full Article
T-Neuro Pharma Announces Publication of Groundbreaking Alzheimer’s Research in Prestigious Journal
ALBUQUERQUE, New Mexico — T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative diagnostics and therapeutics for neurodegenerative diseases, announced the publication of a landmark research article in Proceedings of the National Academy of Sciences(PNAS), a peer-reviewed journal of the National Academy of Sciences….
Antigen-specific age-related memory CD8 T cells induce and track Alzheimer’s-like neurodegeneration
This study changes our view of Alzheimer’s disease (AD) initiation and progression. Mutations promoting cerebral beta-amyloid (Aβ) deposition guarantee rare genetic forms of AD. Thus, the prevailing hypothesis has been that Aβ is central to initiation and progression of all AD, despite contrary animal and…
Evolutionary Selection of APOEɛ4 Encourages Increased Focus on Immunity in Alzheimer’s Disease
Smith and Ashford present a compelling hypothesis on evolution of APOE alleles, namely that ɛ4 prevalence is mediated by immune selection pressure against enteric pathogens. While the ɛ3 allele is more prevalent today, it outcompetedɛ4 only relatively recently, as immune selection pressure for more effective…
JOURNAL OF ALZHEIMER’S DISEASE: Can Immunity Impact Alzheimer’s Disease?
Evolutionary Selection of APOE 4 Encourages Increased Focus on Immunity in Alzheimer’s Disease By: Christopher J. Wheeler Abstract. Smith and Ashford present a compelling hypothesis on evolution of APOE alleles, namely that 4 prevalence is mediated by immune selection pressure against enteric pathogens. While the…
Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
The promise of adaptive cancer immunotherapy in treating highly malignant tumors such as glioblastoma multiforme (GBM) can only be realized through expanding its benefits to more patients. Alleviating various modes of immune suppression has so far failed to achieve such expansion, but exploiting endogenous immune…
Amyloid hypotheses – From widely accepted to hotly debated
The past month has led way to what many in the Alzheimer’s field might consider a “seismic shift”. The controversy began when it was revealed that data underlying the most prominent theory of Alzheimer’s causation – the amyloid hypothesis – was potentially manipulated or even…
CEO Making Strides in the Diagnosis of Alzheimer’s Disease Named One of the Three Fellows for LANL’S Prestigious “LEEP” Program
Albuquerque, NM – Los Alamos National Laboratory recently launched the New Mexico Lab-Embedded Entrepreneur Program (New Mexico LEEP) in January of 2022. Through this program, entrepreneurs are provided a two-year fellowship that focuses on technical solutions to society’s largest concerns. These solutions, also referred to as…
CD103 Deficiency Promotes Autism (ASD) and Attention-Deficit Hyperactivity Disorder (ADHD) Behavioral Spectra and Reduces Age-Related Cognitive Decline
The incidence of autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD), which frequently co-occur, are both rising. The causes of ASD and ADHD remain elusive, even as both appear to involve perturbation of the gut-brain-immune axis. CD103 is an integrin and E-cadherin receptor…